Responses to new research

In a paper published on Wednesday 4 March 2026 by Professor Helen Cross, President of our Medical Advisory Board, new data has been shared from Stoke Therapeutics’ phase 1/2 clinical trial of zorevunersen. To find out more, read our FAQs.

Recent discussion has emerged about the long-term outlook for adults with Dravet Syndrome. Understanding these discussions is crucial for families, caregivers, and healthcare providers planning long-term care.